The FDA-cleared device is designed to be inserted into the nasal cavity to induce the production of natural tears, and is the only such device of its kind, the Dublin-based company said.
“TrueTear is the latest in a long line of innovations that have helped make Allergan a leading global eye care company. We are excited to add this drug-free, drop-free treatment option for adult patients with inadequate tear production to our current portfolio. This milestone truly represents our company’s ongoing commitment to developing eye care products that help improve the lives of patients. For more than 70 years, Allergan has remained focused on delivering the most innovative eye care products in the industry. TrueTear continues the proud heritage of our foundational philosophy: to bring innovative treatments to patients around the world,” US eye care senior VP Jag Dosanjh said in a press release.
FDA approval of the device, which the company won last April, was supported by results from from two clinical trials, which showed the device to be safe and effective for temporarily increasing tear production in adult patients, Allergan said.
“As seen in clinical trials and in my own post-approval experience treating patients, TrueTear provides tiny pulses of energy within the nasal cavity to create tears and may be appropriate for most patients with inadequate tear production. TrueTear is the first device of its kind, providing a temporary increase in tear production with neurostimulation, thereby returning the ocular surface to a more normal physiologic state without prescribing drops or surgery,” Dr. John Sheppard of Norfolk’s Virginia Eye Consultants said in prepared remarks.
Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.
DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Early Registration is now open.